Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLNR | O43193 | 6/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
| ▸ | MGLL | Q99685 | 2/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.37 |
| ▸ | RORC | P51449 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.37 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2851975 | 0.90 | MLNR (0.74) | MLNRKCNH2MGLLPTGDR2 | |
| SCHEMBL1999247 | 0.90 | MLNR (0.67) | MLNRKCNH2MGLLFAAHSETD7 | |
| SCHEMBL2853455 | 0.88 | MLNR (0.69) | MLNRKCNH2MGLLPTGDR2KMT2A | |
| SCHEMBL2853558 | 0.87 | MLNR (0.72) | MLNRKCNH2MGLLFAAHPTGDR2 | |
| SCHEMBL2851448 | 0.86 | MLNR (0.52) | MLNRKCNH2MGLLFAAHPTGDR2 | |
| SCHEMBL1999285 | 0.84 | MLNR (1.00) | MLNR | |
| SCHEMBL2003109 | 0.81 | MLNR (0.69) | MLNRKCNH2MGLLPTGDR2SETD7 | |
| SCHEMBL1999248 | 0.81 | MLNR (0.60) | MLNRKCNH2RORCKMT2ASETD7 | |
| SCHEMBL2853551 | 0.79 | MLNR (0.53) | MLNRKCNH2MGLLFAAHPTGDR2 | |
| SCHEMBL3659038 | 0.79 | MLNR (0.53) | MLNRKCNH2PTGDR2KMT2ACCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256364-A1 | PIPERAZINYL-SULFONAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF GPR38 RECEPTOR MEDIATED DISEASES | GLAXO GROUP LTD. | 2010-10-07 | — | — | US | disclosed |
| EP-2212299-A1 | PIPERAZINYL-SULFONAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF GPR38 RECEPTOR MEDIATED DISEASES | Glaxo Group Limited (GB) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009068552-A1 | PIPERAZINYL-SULFONAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF GPR38 RECEPTOR MEDIATED DISEASES | GLAXO GROUP LIMITED (GB) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256364-A1 | PIPERAZINYL-SULFONAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF GPR38 RECEPTOR MEDIATED DISEASES | GPR68, GPR88, GIPR | MLNR 12/4885KCNH2 2812/4885MGLL 1048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.